help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pratt, C. B.
Right arrow Articles by Meyer, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pratt, C. B.
Right arrow Articles by Meyer, D.
The Oncologist, Vol. 2, No. 1, 1–5, February 1997
© 1997 AlphaMed Press


MEET THE PROFESSOR

Proposal for a New Staging Scheme for Intraocular and Extraocular Retinoblastoma Based on an Analysis of 103 Globes

Charles B. Pratta, James Fontanesib,, Xiaolong Luc,, David M. Parhamd,, Jon Elfervige, David Meyere

a Departments of Hematology/Oncology, b Radiation Oncology, c Biostatistics, and d Pathology and Laboratory Medicine, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA and c Departments of Pediatrics, b Radiation Oncology, and d Pathology, University of Tennessee, Memphis School of Medicine, Memphis, Tennessee, USA and c Vitreoretinal Foundation, Memphis, Tennessee, USA

Correspondence: Charles B. Pratt, M.D., St. Jude Children’s Research Hospital, P.O. Box 318, Memphis, TN 38101-0318, USA. Telephone: 901-495-3300; Fax: 901-521-9005.

Management of retinoblastoma is highly individualized and depends heavily on grouping or staging. In view of evolving methods of imaging and treating retinoblastoma, we have developed and evaluated a revised staging scheme. We analyzed the survival data of 73 patients treated at St. Jude Children’s Research Hospital to compare the ability of the Reese-Ellsworth grouping system, the original St. Jude, and the modified St. Jude staging schemes to predict progression-free survival. None of the staging schemes significantly correlated with progression-free survival. This modified staging scheme provides an instrument for assessing the natural history of retinoblastoma based on ophthalmologic, other clinical, and imaging findings. Because it can identify patients at higher risk, the modified St. Jude scheme may be useful in selecting appropriate therapy regimens for children with retinoblastoma.

Key Words. Retinoblastoma • Reese-Ellsworth groupings • Staging • Outcome







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1997 by AlphaMed Press.